TY - STD TI - 1Torres J, Bonovas S, Doherty G, et. al. ECCO Guidelines on Therapeutics in Crohn’s Disease: medical treatment. Journal of Crohn's and Colitis 2019. ID - ref1 ER - TY - JOUR AU - Ko, C. W. AU - Singh, S. AU - Feuerstein, J. D. PY - 2019 DA - 2019// TI - AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis JO - Gastroenterology VL - 156 UR - https://doi.org/10.1053/j.gastro.2018.12.009 DO - 10.1053/j.gastro.2018.12.009 ID - Ko2019 ER - TY - STD TI - 3Harbord M, Eliakim R, Bettenworth D, et. al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769–84. ID - ref3 ER - TY - JOUR AU - Bressler, B. AU - Marshall, J. K. AU - Bernstein, C. N. PY - 2015 DA - 2015// TI - clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the toronto consensus JO - Gastroenterology VL - 148 ID - Bressler2015 ER - TY - JOUR AU - Panaccione, R. AU - Steinhart, A. H. AU - Bressler, B. PY - 2019 DA - 2019// TI - Canadian association of gastroenterology clinical practice guideline for the management of luminal Crohn’s disease JO - J Can Assoc Gastroenterol VL - 2 UR - https://doi.org/10.1093/jcag/gwz019 DO - 10.1093/jcag/gwz019 ID - Panaccione2019 ER - TY - JOUR AU - Hanauer, S. B. AU - Feagan, B. G. AU - Lichtenstein, G. R. PY - 2002 DA - 2002// TI - Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial JO - Lancet VL - 359 UR - https://doi.org/10.1016/S0140-6736(02)08512-4 DO - 10.1016/S0140-6736(02)08512-4 ID - Hanauer2002 ER - TY - JOUR AU - Rutgeerts, P. AU - Sandborn, W. J. AU - Feagan, B. G. PY - 2005 DA - 2005// TI - Infliximab for induction and maintenance therapy for ulcerative colitis JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa050516 DO - 10.1056/NEJMoa050516 ID - Rutgeerts2005 ER - TY - JOUR AU - Vande Casteele, N. AU - Khanna, R. AU - Levesque, B. G. PY - 2015 DA - 2015// TI - The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease JO - Gut VL - 64 UR - https://doi.org/10.1136/gutjnl-2014-307883 DO - 10.1136/gutjnl-2014-307883 ID - Vande Casteele2015 ER - TY - JOUR AU - Papamichael, K. AU - Rakowsky, S. AU - Rivera, C. PY - 2018 DA - 2018// TI - Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis JO - Aliment Pharmacol Ther VL - 47 UR - https://doi.org/10.1111/apt.14458 DO - 10.1111/apt.14458 ID - Papamichael2018 ER - TY - JOUR AU - Moore, C. AU - Corbett, G. AU - Moss, A. C. PY - 2016 DA - 2016// TI - Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease JO - J Crohn's Colitis VL - 10 UR - https://doi.org/10.1093/ecco-jcc/jjw007 DO - 10.1093/ecco-jcc/jjw007 ID - Moore2016 ER - TY - STD TI - 11Cellier C, Sahmoud T, Froguel E, et. al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231–5. ID - ref11 ER - TY - JOUR AU - Peyrin-Biroulet, L. AU - Reinisch, W. AU - Colombel, J. -. F. PY - 2014 DA - 2014// TI - Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial JO - Gut VL - 63 UR - https://doi.org/10.1136/gutjnl-2013-304984 DO - 10.1136/gutjnl-2013-304984 ID - Peyrin-Biroulet2014 ER - TY - JOUR AU - Domenech, E. AU - Zabana, Y. AU - Garcia-Planella, E. PY - 2010 DA - 2010// TI - Clinical outcome of newly diagnosed Crohn’s disease: a comparative, retrospective study before and after infliximab availability JO - Aliment Pharmacol Ther VL - 31 ID - Domenech2010 ER - TY - JOUR AU - Cannom, R. R. AU - Kaiser, A. M. AU - Ault, G. T. PY - 2009 DA - 2009// TI - Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? JO - Am Surg VL - 75 UR - https://doi.org/10.1177/000313480907501025 DO - 10.1177/000313480907501025 ID - Cannom2009 ER - TY - JOUR AU - Jones, D. W. AU - Finlayson, S. R. PY - 2010 DA - 2010// TI - Trends in surgery for Crohn's disease in the era of infliximab JO - Ann Surg VL - 252 UR - https://doi.org/10.1097/SLA.0b013e3181e61df5 DO - 10.1097/SLA.0b013e3181e61df5 ID - Jones2010 ER - TY - JOUR AU - Levesque, B. G. AU - Sandborn, W. J. AU - Ruel, J. PY - 2015 DA - 2015// TI - Converging goals of treatment of inflammatory bowel disease from clinical trials and practice JO - Gastroenterology VL - 148 ID - Levesque2015 ER - TY - JOUR AU - Bouguen, G. AU - Siproudhis, L. AU - Gizard, E. PY - 2013 DA - 2013// TI - Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab JO - Clin Gastroenterol Hepatol VL - 11 ID - Bouguen2013 ER - TY - JOUR AU - Bessissow, T. AU - Lemmens, B. AU - Ferrante, M. PY - 2012 DA - 2012// TI - Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing JO - Am J Gastroenterol VL - 107 UR - https://doi.org/10.1038/ajg.2012.301 DO - 10.1038/ajg.2012.301 ID - Bessissow2012 ER - TY - JOUR AU - Lemmens, B. AU - Arijs, I. AU - Assche, G. PY - 2013 DA - 2013// TI - Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis JO - Inflamm Bowel Dis VL - 19 UR - https://doi.org/10.1097/MIB.0b013e318280e75f DO - 10.1097/MIB.0b013e318280e75f ID - Lemmens2013 ER - TY - JOUR AU - Zenlea, T. AU - Yee, E. U. AU - Rosenberg, L. PY - 2016 DA - 2016// TI - Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study JO - Am J Gastroenterol VL - 111 UR - https://doi.org/10.1038/ajg.2016.50 DO - 10.1038/ajg.2016.50 ID - Zenlea2016 ER - TY - JOUR AU - Battat, R. AU - Duijvestein, M. AU - Guizzetti, L. PY - 2019 DA - 2019// TI - Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials JO - Am J Gastroenterol VL - 114 UR - https://doi.org/10.14309/ajg.0000000000000111 DO - 10.14309/ajg.0000000000000111 ID - Battat2019 ER - TY - STD TI - Services CfDEaH. Ulcerative colitis: Clinical Trial Endpoints Guidance for Industry. US Food and Drug Administration. In: Administration USFaD, ed., 2016. ID - ref22 ER - TY - JOUR AU - Peyrin-Biroulet, L. PY - 2014 DA - 2014// TI - Deep remission in Crohn's disease: is it the end of the placebo effect? JO - Clin Gastroenterol Hepatol VL - 12 UR - https://doi.org/10.1016/j.cgh.2013.07.031 DO - 10.1016/j.cgh.2013.07.031 ID - Peyrin-Biroulet2014 ER - TY - STD TI - Christensen B, Erlich J, Gibson PR, et. al. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn’s Disease than Endoscopic Healing. Clin Gastroenterol Hepatol in press. ID - ref24 ER - TY - STD TI - Geboes K, Rutgeerts P, Olson A, et. al. Infliximab Results in Reduction of Inflammation and Inflammatory Markers in the Mucosa of Ulcerative Colitis Patients: The ACT 1 Trial: 789. Am J Gastroenterol 2005;100. ID - ref25 ER - TY - JOUR AU - Molander, P. AU - Sipponen, T. AU - Kemppainen, H. PY - 2013 DA - 2013// TI - Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD JO - J Crohn's Colitis VL - 7 UR - https://doi.org/10.1016/j.crohns.2012.10.018 DO - 10.1016/j.crohns.2012.10.018 ID - Molander2013 ER - TY - JOUR AU - Feuerstein, J. D. AU - Nguyen, G. C. AU - Kupfer, S. S. PY - 2017 DA - 2017// TI - American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease JO - Gastroenterology VL - 153 UR - https://doi.org/10.1053/j.gastro.2017.07.032 DO - 10.1053/j.gastro.2017.07.032 ID - Feuerstein2017 ER - TY - JOUR AU - Bortlik, M. M. PY - 2013 DA - 2013// TI - Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease JO - J Crohn's Colitis VL - 7 UR - https://doi.org/10.1016/j.crohns.2012.10.019 DO - 10.1016/j.crohns.2012.10.019 ID - Bortlik2013 ER - TY - JOUR AU - Papamichael, K. AU - Cheifetz, A. S. AU - Melmed, G. Y. PY - 2019 DA - 2019// TI - Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases JO - Clin Gastroenterol Hepatol VL - 17 ID - Papamichael2019 ER - TY - JOUR AU - Harvey, R. F. AU - Bradshaw, J. M. PY - 1980 DA - 1980// TI - A simple index of Crohn's-disease activity JO - Lancet VL - 1 UR - https://doi.org/10.1016/S0140-6736(80)92767-1 DO - 10.1016/S0140-6736(80)92767-1 ID - Harvey1980 ER - TY - JOUR AU - Lewis, J. D. AU - Chuai, S. AU - Nessel, L. PY - 2008 DA - 2008// TI - Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis JO - Inflamm Bowel Dis VL - 14 UR - https://doi.org/10.1002/ibd.20520 DO - 10.1002/ibd.20520 ID - Lewis2008 ER - TY - JOUR AU - Ruopp, M. D. AU - Perkins, N. J. AU - Whitcomb, B. W. PY - 2008 DA - 2008// TI - Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection JO - Biometrical J VL - 50 UR - https://doi.org/10.1002/bimj.200710415 DO - 10.1002/bimj.200710415 ID - Ruopp2008 ER - TY - JOUR AU - Ungar, B. AU - Levy, I. AU - Yavne, Y. PY - 2016 DA - 2016// TI - Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases JO - Clin Gastroenterol Hepatol VL - 14 ID - Ungar2016 ER - TY - JOUR AU - Papamichael, K. AU - Rakowsky, S. AU - Rivera, C. PY - 2018 DA - 2018// TI - Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn’s disease JO - Inflamm Bowel Dis VL - 24 UR - https://doi.org/10.1093/ibd/izy132 DO - 10.1093/ibd/izy132 ID - Papamichael2018 ER - TY - JOUR AU - Yarur, A. J. AU - Kanagala, V. AU - Stein, D. J. PY - 2017 DA - 2017// TI - Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease JO - Aliment Pharmacol Ther VL - 45 UR - https://doi.org/10.1111/apt.13970 DO - 10.1111/apt.13970 ID - Yarur2017 ER - TY - JOUR AU - Tkacz, J. AU - Lofland, J. H. AU - Vanderpoel, J. PY - 2014 DA - 2014// TI - Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review JO - Am Health Drug Benefits VL - 7 ID - Tkacz2014 ER - TY - JOUR AU - Casteele, N. V. AU - Ferrante, M. AU - Assche, G. PY - 2015 DA - 2015// TI - Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease JO - Gastroenterology VL - 148 ID - Casteele2015 ER -